Did Organigram Global beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Organigram Global year over year?

What is Organigram Global's latest dividend and current dividend yield?

What factors drove the changes in Organigram Global's revenue and profit?

What were the key takeaways from Organigram Global’s earnings call?

What guidance did Organigram Global's management provide for the next earnings period?

What were the key takeaways from Organigram Global's earnings call?

What is the market's earnings forecast for Organigram Global next quarter?

- **Market Dominance**: #1 Canadian LP with 11.6% share, 20.4% vape leadership, and SHRED's 81% repurchase rate.
- **Revenue Surge**: Q3 net $70.8M (+72% YoY), adj. EBITDA $5.7M, free cash flow $5M.
- **International Growth**: $7.4M intl. rev. (+208% YoY), U.S. beverages in 25 states, and EU GMP pending for margin boost.
- **Operational Efficiency**: $4.2M synergies realized, 34% gross margin, and $5M free cash flow.
- **Leadership Transition**: CEO Beena Goldenberg retiring, but confident in team and 40%+ FY26 margin target.

**【CEO Summary Section】**
- **Market Leadership**: Maintained #1 national market share at 11.6%, up 2.5 points year-over-year, with 20.4% share in vapes and 10.6% in flower. SHRED brand achieved 81% repurchase rate in milled flower.
- **Operational Growth**: Harvested 24,000 kg at Moncton (15% QoQ increase), with 14,000 kg annual capacity expansion. Launched SHRED Mac 10 edibles, driving 50 bps sequential share gain to 16.1%.
- **International Expansion**: Q3 international revenue $7.4M (+208% YoY), driven by Germany and Australia. U.S. beverages now in 25 states with 9 SKUs, including Fetch soda line.
- **Integration Progress**: $4.2M synergies realized (annualized $11M), with ERP transition complete and London DC set to reduce freight costs by $3.4M/year.

**【CFO Financial Commentary】**
- **Revenue Records**: Q3 net revenue $70.8M (+72% YoY), adj. EBITDA $5.7M (+64% YoY). Free cash flow $5M, up from $0.5M in Q2.
- **Gross Margin**: 34% (down 200 bps YoY due to Motif drag), with 35% full-year target and 40%+ FY26 outlook. Organigram standalone margin 37% vs. Motif at 29%.
- **Cost Efficiency**: Operating expenses 40% of net revenue, down 5% YoY. $2.7M COGS savings from Elmer expansion and $1.4M annual biomass savings.

**【Q&A Highlights】**
- **GMP Certification**: EU GMP delayed due to regulatory scrutiny, but expected to boost margins via direct exports. Current international flower sales at lower margins due to middlemen.
- **Capacity Strategy**: Reevaluating $8M Moncton expansion to optimize for drying vs. growing. 14,000 kg annualized from LED upgrades and nutrient improvements.
- **U.S. Investment**: Focused on beverages and genetics via Filos partnership. No immediate plant-touching plans despite Schedule III hopes.
- **Synergy Outlook**: On track for $15M total synergies, with $4.2M realized and $10.8M remaining.


Organigram Global Inc. (OGI) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 net revenue up 74% YoY to $65.6M, fueled by Motif and intl growth.
- **Canada Dominance**: 21.7% vape share, 40%+ milled flower; 177% YoY intl sales growth.
- **US Beverage Momentum**: 10-state distribution, $1M+ US sales, 5.4% national market share.
- **Capacity Expansion**: $16M+ projects to add 14,000kg flower capacity.
- **Profitability Goals**: 40% gross margin by H2 FY26, $15M annual synergies.
- **Cash Strength**: $83.4M cash, $58M M&A pool for intl expansion.


**【CEO Opening Remarks】**
- **Record-Q2 Revenue**: Achieved $65.6M net revenue, up 74% YoY, driven by Motif integration and international expansion.
- **Canada Market Leadership**: 21.7% vape market share, 40%+ in milled flower; 177% YoY growth in international sales ($6.1M).
- **US Hemp Beverage Growth**: 10-state distribution, $1M+ Q2 US retail sales, with 5.4% national beverage market share.
- **Capacity Expansion**: $9M LED upgrade for +7,000kg flower capacity; $7M London warehouse project for additional 7,000kg.
- **Motif Synergies**: $15M annual synergies expected FY26 vs. $10M prior guidance.

**【CFO Financial Highlights】**
- **Adjusted EBITDA**: $4.9M (vs. -$1M YoY), with $6.3M H1 total.
- **Gross Margin**: 33% (vs. 31% YoY), 37% standalone Organigram margin.
- **Net Income**: $42.5M (vs. -$27.1M YoY), driven by BAT investment gains.
- **Cash Position**: $83.4M, with $58M remaining in Jupiter M&A pool.
- **CapEx**: $8-10M FY25, $9M for Moncton LED upgrade.

**【Q&A Key Takeaways】**
- **International Balancing Act**: Prioritize high-margin intl sales while maintaining domestic leadership (e.g., Big Bag O' Buds growth).
- **Gross Margin Target**: 40% by H2 FY26, driven by intl expansion and Motif synergies.
- **US Beverage Strategy**: Invest in distribution and sampling to build trial; 10-state presence, DTC launch Q3.
- **Cash Flow Outlook**: Q3/Q4 seasonal strength to drive positive cash flow, offsetting Q2 working capital build.


Organigram Global Inc. (OGI) Q2 2025 Earnings Call Transcript

- **Market Leadership**: #1 in Canada for vapes (22% share) and pre-rolls, with Edison Sonics gummies entering top 10 in key provinces.
- **International Surge**: International sales +230% YOY to $3.3M; Germany medical market 4x growth since Q2 2024, targeting direct exports post-EU GMP.
- **Operational Efficiency**: 21% seed-based cultivation, 15% yield gains from LED upgrades, $400K annual savings from distribution optimization.
- **Motif Synergies**: $10M annual run rate achievable in 24 months; Q3/Q4 2025 to see $5M of $10M annual synergies flow through P&L.
- **Financial Strength**: $71.2M cash, $113M pro-forma post-BAT follow-on; 2025 adj. EBITDA expected to outperform 2024 with Q3/Q4 strength.


**【CEO Opening Remarks】**
- Q1 FY2025 revenue growth driven by 15% YOY expansion in recreational business, supported by flagship SHRED and BOXHOT brands.
- Market share expanded 500bps YOY to become #1 in vapes (22% share) and pre-rolls, with Edison Sonics gummies exceeding expectations in premium segment.
- International sales surged 230% YOY to $3.3M, with Germany and Australia key growth markets. EU GMP certification for Moncton facility expected Q2 to enable direct exports and higher margins.
- Operational efficiency improvements: 21% of harvests from seed-based cultivation, 15% yield increase from LED upgrades, and $400K annual savings from Winnipeg distribution optimization.
- Motif integration on track to deliver $10M annual synergies, with early wins in manufacturing, sales, and innovation.

**【CFO Financial Highlights】**
- Net revenue $42.7M (+17% YOY), adj. gross margin 33% (+200bps YOY) driven by higher ASPs and international sales.
- Adjusted EBITDA $1.4M vs. $0.1M prior year, with back-half 2025 growth expected from synergies and seasonality.
- Net loss $23M due to one-time $18.9M fair value loss on BAT shares; cash position $71.2M with $113M pro-forma including BAT follow-on.
- 2025 capex: $8-10M sustaining + $16M for Moncton expansion; 2025 adj. EBITDA expected to outperform 2024 with Q3/Q4 strength.

**【Q&A Key Takeaways】**
- **Germany Strategy**: $21M investment in Sanity Group positions for recreational pilot projects; direct exports post-GMP certification to reduce costs and capture premium 2.0 products.
- **US Hemp Expansion**: Jupiter Pool investments targeting Hemp Delta-9 market; cautious on ring-fenced investments in regulated states.
- **Policy Outlook**: Both federal election outcomes seen positive for industry; excise tax reform and harmonized national stamp likely under conservative government.
- **Profitability Path**: Q2 synergies begin flowing, with $5M of $10M annual run rate achieved in 2025H2; 35%+ gross margin target with international mix optimization.


Organigram Holdings Inc. (OGI) Q1 2025 Earnings Call Transcript

Organigram Holdings Inc. (OGI) Q2 2024 Earnings Call Transcript

Organigram Holdings Inc. (OGI) Q1 2024 Earnings Call Transcript

- **Market Leadership**: #1 in gummies, hash, and milled flower; #3 in pre-rolls and flower, with SHRED pre-roll sales up 54%.
- **Profitability Focus**: $10M+ savings from 2024 cost-cutting initiatives; targeting H2 2024 free cash flow with optimized pre-roll production.
- **International Growth**: 25% intl sales growth to $18.9M; new Germany/UK supply agreements to expand THCV exports.
- **Risk Mitigation**: $210M impairment charges highlight THC inflation risks; advocating for testing reforms to level playing field.
- **Strategic Investments**: $124.6M BAT follow-on investment for Jupiter global expansion; seed-based production to cut costs by 30%+.

**【CEO Summary Section】**
- Organigram achieved significant market share growth in 2023, including becoming the #1 in gummies, hash, and milled flower, and #3 in pre-rolls and flower. 
- SHRED brand saw 54% pre-roll sales growth, driven by tube-style pre-rolls, and THCV gummies ranked #7 in a portfolio of 13 SKUs.
- Invested $29M in 2023 CapEx for efficiency improvements, with $10M in savings expected in 2024 from automation and seed-based production.
- International sales grew 25% to $18.9M, but Q4 delays due to Israel testing requirements impacted margins.
- Secured new supply agreements with Sanity Group (Germany) and 4C Labs (UK) for THCV exports.

【CFO Financial Commentary】**
- Fiscal 2023 gross revenue increased 12% to $205.4M, net revenue up 11% to $184.3M, driven by recreational (+$15.1M) and international (+$3.7M) sales.
- Adjusted EBITDA was -$2.4M in Q4 but +$6M for the year, despite $210M impairment charges linked to THC inflation.
- Ended with $51.8M cash (including $33.9M unrestricted) and no debt, positioning for free cash flow in H2 2024.
- 2024 CapEx reduced to maintenance level, with focus on optimizing existing infrastructure.

【Q&A Highlights】**
- **Gross Margin Dynamics**: International sales (30%+ margins) key to margin recovery; Q4 2024+ shipments to Germany/UK expected to reduce lumpiness. 
- **THC Inflation**: Fraudulent THC claims (e.g., 30%+ flower) distort market; company advocating for testing reforms. 
- **Industry Consolidation**: 20+ LPs in tax arrears; Organigram expects 2024 to see accelerated closures as CRA enforces payments. 
- **THCV Strategy**: Vape launch imminent; EU GMP certification audit expected early 2024 to enable faster international shipments.
- **Free Cash Flow**: H2 2024 target achievable with improved pre-roll fulfillment and resumption of intl shipments.


Actual				-0.1222	-1.4759	-0.6109	-0.5247	-0.8023	-0.0444	-0.2478	-0.0119	-0.0315	-0.0254	-0.0609		-0.0616	-1.9526		-0.1321	-0.1675	0.0205	-0.0333	-0.139	0.2223	-0.0367	-0.1983	-0.0073
Forecast				-0.0521	-0.1113	-0.1018	-0.1143	-0.1387	-0.1206	-0.1311	-0.1073	-0.0728	-0.0632	-0.0609		-0.0586	-0.0532		-0.089	-0.064	-0.0494	-0.0282	-0.0234	-0.0257	-0.008	-0.0048	-0.0069
Surprise	0.00%	0.00%	0.00%	-134.55%	-1226.06%	-500.10%	-359.06%	-478.44%	+63.18%	-89.02%	+88.91%	+56.73%	+59.81%	0.00%	0.00%	-5.12%	-3570.30%	0.00%	-48.43%	-161.72%	+141.50%	-18.09%	-494.02%	+964.98%	-358.75%	-4031.25%	-5.80%

OGI

OGI fundamentals

OGI Q1 2026 Earnings

Earnings Call

You can ask Aime

OGI

OGI fundamentals

OGI Q1 2026 Earnings

Earnings Call

OGI Earnings Call Summary for Q1/20268:00 AM on Feb 10, 2026

OGI Earnings Call Summary for Q4/20258:00 AM on Dec 16, 2025

OGI Earnings Call Summary for Q3/20258:00 AM on Aug 13, 2025

OGI Earnings Call Summary for Q2/20258:00 AM on May 12, 2025

OGI Earnings Call Summary for Q1/20258:00 AM on Feb 11, 2025

You can ask Aime